当前位置：
X-MOL 学术
›
Ther. Adv. Med. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
Therapeutic Advances in Medical Oncology ( IF 4.3 ) Pub Date : 2019-05-10 , DOI: 10.1177/1758835919846421 Gemma Bruera 1 , Silvia Massacese 2 , Francesco Pepe 3 , Umberto Malapelle 3 , Antonella Dal Mas 4 , Eugenio Ciacco 2 , Giuseppe Calvisi 4 , Giancarlo Troncone 3 , Maurizio Simmaco 5 , Enrico Ricevuto 6
Therapeutic Advances in Medical Oncology ( IF 4.3 ) Pub Date : 2019-05-10 , DOI: 10.1177/1758835919846421 Gemma Bruera 1 , Silvia Massacese 2 , Francesco Pepe 3 , Umberto Malapelle 3 , Antonella Dal Mas 4 , Eugenio Ciacco 2 , Giuseppe Calvisi 4 , Giancarlo Troncone 3 , Maurizio Simmaco 5 , Enrico Ricevuto 6
Affiliation
Therapeutic strategy of metastatic colorectal cancer (MCRC) is planned by predictive/prognostic biomarkers and the patients’ fitness for selected targeted drugs, antivascular endothelial growth factor (anti-VEGF) or anti-epidermal growth factor receptor (anti-EGFR), associated with doublet or more intensive triplet chemotherapy, properly weighing the expected clinical outcome with toxicity in individual patients.1
中文翻译：
三联化疗联合西妥昔单抗治疗 RAS 野生型转移性结直肠癌患者的强化一线 FIr-C/FOx-C 关联：初步 II 期数据和药物基因组生物标志物对个体限制性毒性综合征的预测
转移性结直肠癌 (MCRC) 的治疗策略是通过预测/预后生物标志物和患者对选定的靶向药物、抗血管内皮生长因子 (anti-VEGF) 或抗表皮生长因子受体 (anti-EGFR) 的适应性来规划的，与双联或更密集的三联化疗，适当权衡个体患者的预期临床结果和毒性。1
更新日期：2019-05-10
中文翻译：
三联化疗联合西妥昔单抗治疗 RAS 野生型转移性结直肠癌患者的强化一线 FIr-C/FOx-C 关联：初步 II 期数据和药物基因组生物标志物对个体限制性毒性综合征的预测
转移性结直肠癌 (MCRC) 的治疗策略是通过预测/预后生物标志物和患者对选定的靶向药物、抗血管内皮生长因子 (anti-VEGF) 或抗表皮生长因子受体 (anti-EGFR) 的适应性来规划的，与双联或更密集的三联化疗，适当权衡个体患者的预期临床结果和毒性。1
京公网安备 11010802027423号